Trial Profile

A Phase 1a trial of EVX-B1 for S. aureus in skin and soft tissue infections (SSTIs)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EVX-B1 (Primary)
Indications Skin infections
Focus Adverse reactions
Sponsors Evaxion Biotech

Most Recent Events

28 May 2024 According to an Evaxion media release, the company plans Conclusion of final MTA study with potential partner in Q1 2024
20 Nov 2021 New trial record
09 Nov 2021 According to an Evaxion media release, the company plans Phase 1a IND,CTA filing for EVX-B1 for S. aureus in skin and soft tissue infections (SSTIs) H2 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com